StockNews.com Initiates Coverage on Check-Cap (NASDAQ:CHEK)

Equities research analysts at StockNews.com assumed coverage on shares of Check-Cap (NASDAQ:CHEK) in a report released on Tuesday. The brokerage set a “sell” rating on the medical research company’s stock.

Check-Cap Stock Down 3.1 %

Shares of CHEK stock opened at $2.22 on Tuesday. Check-Cap has a 12-month low of $1.27 and a 12-month high of $4.63. The company has a market capitalization of $12.99 million, a P/E ratio of -0.74 and a beta of 0.28. The firm has a 50-day moving average price of $2.25 and a 200 day moving average price of $2.57.

About Check-Cap

Check-Cap Ltd., a clinical stage medical diagnostics company, engages in the development of a capsule-based screening technology that utilizes ultra-low-dose X-rays to scan the inner lining of the colon for precancerous polyps, and other structural abnormalities in Israel. Its C-Scan system consists of C-Scan Cap, an X-ray scanning capsule for detection of suspected polyps; C-Scan Track, a disposable system attached to the patient's back through biocompatible adhesive skin patches; and C-Scan View software, a client/server-based application that enables procedure data download from the C-Scan Track, data analysis, and report generation.